Leerink Partnrs Decreases Earnings Estimates for Insulet

Insulet Corporation (NASDAQ:PODD) – Research analysts at Leerink Partnrs reduced their FY2025 EPS estimates for Insulet in a report issued on Monday, July 14th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will earn $4.16 per share for the year, down from their prior estimate of $4.18. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s Q4 2025 earnings at $1.32 EPS and FY2026 earnings at $5.53 EPS.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter last year, the business earned $0.73 EPS.

A number of other research analysts have also issued reports on PODD. Truist Financial assumed coverage on shares of Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 price objective for the company. Oppenheimer raised their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 price objective for the company in a report on Tuesday, May 13th. Barclays increased their target price on shares of Insulet from $234.00 to $266.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company set a $322.00 price target on shares of Insulet in a report on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus price target of $321.00.

Insulet Stock Down 0.7%

Shares of NASDAQ PODD opened at $289.99 on Tuesday. The company has a 50 day simple moving average of $308.58 and a 200 day simple moving average of $280.50. The firm has a market cap of $20.41 billion, a PE ratio of 52.16, a price-to-earnings-growth ratio of 2.61 and a beta of 1.35. Insulet has a 1 year low of $173.00 and a 1 year high of $329.33. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63.

Institutional Trading of Insulet

Several hedge funds have recently bought and sold shares of the business. Mather Group LLC. grew its position in Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares during the period. Ballentine Partners LLC grew its position in Insulet by 13.9% in the 2nd quarter. Ballentine Partners LLC now owns 2,022 shares of the medical instruments supplier’s stock valued at $635,000 after purchasing an additional 246 shares during the period. Cigna Investments Inc. New acquired a new stake in Insulet in the 2nd quarter valued at $220,000. Sheets Smith Wealth Management grew its position in Insulet by 6.1% in the 2nd quarter. Sheets Smith Wealth Management now owns 2,107 shares of the medical instruments supplier’s stock valued at $662,000 after purchasing an additional 122 shares during the period. Finally, GAMMA Investing LLC grew its position in Insulet by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 2,918 shares of the medical instruments supplier’s stock valued at $917,000 after purchasing an additional 389 shares during the period.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president owned 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.39% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.